Table 5.

Frequency of Adverse Events in Placebo-Controlled Studies of Pramlintide in Type 1 Diabetes

Trial	Any Nausea %	Severe Nausea %	Any Anorexiaaor Reduced Appetite %	Severe Anorexia or Reduced Appetite %	Any Vomiting %	Severe Vomiting %
Edelman et al, 20065
Pramlintide	48.5–95.1b	4.0–7.3	6.9–14.6	0.0	11.9–17.1	2.4–5.9
Placebo	36.1	0.7	2.0	0.0	6.1	0.7
Whitehouse et al, 200210
Pramlintide	46.5	6.2	17.7	2.5	11.5	2.1
Placebo	21.9	1.7	2.1	0.0	8.0	0.4
Ratner et al, 20047
Pramlintide	47.9–59.0	5.8–8.5	11.0–18.0	0.6–1.9	9.8–12.0	0.6–1.8
Placebo	12.0	1.3	2.6	0.0	6.5	0.6

^aAnorexia was defined as decreased appetite, early satiety or gastric fullness, loss of appetite, or no appetite.

^bThe rate of 95.1% occurred in persons in the pramlintide 30-μg group.